Literature DB >> 2373859

Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.

M J Campbell1, L Esserman, N E Byars, A C Allison, R Levy.   

Abstract

The roles of humoral and cellular antitumor immune responses induced by immunization with tumor-derived idiotypic IgM were studied in a syngeneic, transplantable B cell lymphoma (38C13) of C3H mice. Id vaccination with keyhole limpet hemocyanin-conjugated Id induced protection against a subsequent lethal tumor challenge. Such immunizations elicited anti-idiotypic antibodies that were cytotoxic in in vitro antibody-dependent cellular cytotoxicity assays as well as in vivo passive transfer experiments. L3T4+ T cells, which proliferated in vitro in response to the specific Id protein, were also induced. However, cells mediating direct cytotoxicity, either in vitro or in vivo, were not observed in the lymph nodes, spleens, or peritoneal cavity of immune mice or at the site of tumor regression as demonstrated by using a tumor sponge implantation model. In addition, in vitro sensitization of immune lymphocytes against 38C13 tumor cells failed to induce cytotoxicity. Immunization with lipid conjugated Id also elicited a T cell proliferative response but failed to induce anti-idiotypic antibodies and did not confer resistance to tumor growth. These results suggest that anti-idiotypic antibodies play the major role in the destruction of 38C13 tumor cells. However, in vivo depletion of L3T4+ or Lyt-2+ cells from 38C-Id-keyhole limpet hemocyanin-immunized mice resulted in diminished protection against a tumor challenge. Thus, although humoral responses appear to play the predominant part in tumor destruction, cellular responses are also required for the full expression of antitumor immunity in this system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373859

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Sterile filtration of a parenteral emulsion.

Authors:  D M Lidgate; T Trattner; R M Shultz; R Maskiewicz
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

2.  Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.

Authors:  Gregory Kanter; Junhao Yang; Alexei Voloshin; Shoshana Levy; James R Swartz; Ronald Levy
Journal:  Blood       Date:  2006-12-12       Impact factor: 22.113

3.  Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

Authors:  Kamran Kafi; David J Betting; Reiko E Yamada; Michael Bacica; Kristopher K Steward; John M Timmerman
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

Review 4.  Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Authors:  Maurizio Bendandi
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 5.  Clinical utilization of chemokines to combat cancer: the double-edged sword.

Authors:  Chiara Dell'Agnola; Arya Biragyn
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

6.  Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.

Authors:  G J Weiner; H M Liu; J E Wooldridge; C E Dahle; A M Krieg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Authors:  Suzanne N Franki; Kristopher K Steward; David J Betting; Kamran Kafi; Reiko E Yamada; John M Timmerman
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

Review 8.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

9.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.

Authors:  Michael J Campbell; Wendy S Wollish; Margaret Lobo; Laura J Esserman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.